Tuberous sclerosis complex is well known to pediatric neurologists. Its clinical manifestations of skin lesions, seizures, and mental retardation make tuberous sclerosis complex a prototype for the neurocutaneous disorders. Although genetically distinct, neurologists often think of neurofibromatosis type 1 and tuberous sclerosis complex as similar diseases, and in fact neurofibromatosis type 1 and tuberous sclerosis complex do share a commonality because they both have cutaneous and neurologic manifestations, they both have a high spontaneous mutation rate around 50%, and both may cause variable manifestations among affected individuals from the same family.',' Furthermore, some of the basic questions regarding both disorders revolve around the mechanisms of the disordered cellular proliferation and the disordered tissue organization that characterize both disorders.
With the discovery of the chromosome 17 locus for the gene of neurofibromatosis in 1990,3~4 there was optimism that a better understanding of the etiology of neurofibromatosis type 1 would soon be at hand. That optimism has been rewarded, and progress in the basic pathophysiology of neurofibromatosis type 1 has leapfrogged past that of tuberous sclerosis complex. The neurofibromatosis type 1 gene and gene product (neurofibromin) have been described and are rapidly being characterized.5 Because of the discovery of a major genetic linkage for tuberous sclerosis complex on chromosome 16,6 6 there is now optimism that rapid improvements will be made in understanding the pathogenesis of tuberous sclerosis complex.
Etiology of Tuberous Sclerosis Complex '
In addition to both entities having cutaneous and neurologic features, neurofibromatosis type 1 (von Recklinghausen's neurofibromatosis) and tuberous sclerosis complex also share descriptive input from von Recklinghausen, who described the cerebral sclerosis and cardiac tumors of a child with tuberous sclerosis complex in 1862.~ Despite the long history of tuberous sclerosis complex, the appreciation of its autosomal dominant inheritance, the increasing diagnosis of tuberous sclerosis complex by practitioners, and the visibility conferred upon tuberous sclerosis complex by publication of the monograph Tuberous Sclerosis by Gomez,7 the etiology of tuberous sclerosis complex defied discovery until 1987, when Fryer et al8 demonstrated that the inheritance of tuberous sclerosis complex in several multigenerational tuberous sclerosis complex families was linked to that of the ABO blood groups. That is, the two traits were coinherited. By demonstrating a lod score (log of the odds in favor of linkage) greater than 3, Fryer et al were able to conclude that a genetic locus for tuberous sclerosis complex was at or near that for the ABO blood groups on chromosome 9q34. The discovery of the tuberous sclerosis complex locus on 9q34 was greeted with enthusiasm, and investigators rapidly began working to delimit the area of the potential tuberous sclerosis complex gene. Using a DNA marker, v-abl, linkage of tuberous sclerosis complex to the region of 9q34 was confirmed,9 and DNA tests were even employed on a limited ba-sis for prenatal exclusion of tuberous sclerosis complex.l° However, independent groups of investigators were unable to corroborate the linkage of tuberous sclerosis complex to the ABO IOCUS, 11 -13 and in a group of tuberous sclerosis complex families, Kandt et a111 excluded linkage of tuberous sclerosis complex for a genetic distance of 20 cM encompassing the region of the ABO locus. Although a specific location for a second tuberous sclerosis complex gene was not evident, it was becoming clear that another locus must exist to account for the tuberous sclerosis complex families that were not linked to 9q34. 11, 14 With the possibility that there was more than one gene locus for tuberous sclerosis complex, there was another similarity to neurofibromatosis. At least two genetic types of neurofibromatosis are recognized : neurofibromatosis type 1 (chromosome 17) and neurofibromatosis type 2 (chromosome 22).1,2 There is, however, a basic difference between the situation with neurofibromatosis and that for tuberous sclerosis complex. With regard to neurofibromatosis, it had long been felt that more than one disorder was represented by the name neurofibromatosis. Clinicians were comfortable that there were at least two types of neurofibromatosis: peripheral neurofibromatosis and central neurofibromatosis.
This clinical distinction was later verified by finding the chromosomal localizations for peripheral neurofibromatosis (neurofibromatosis type 1) and central neurofibromatosis (neurofibromatosis type 2).1,2
In contrast, tuberous sclerosis complex has until recently been considered a single disorder, and although individual cases have remarkable variability in their clinical manifestations, subtypes of tuberous sclerosis complex have not been apparent. Therefore, the emerging evidence that genetic locus heterogeneity existed for tuberous sclerosis complex (ie, more than one gene locus for tuberous sclerosis complex) was a surprise to investigators.
In 1990, Smith et al 15 suggested that a second locus for tuberous sclerosis complex was located on chromosome llq. Many investigators then retested families, particularly those not linked to chromosome 9, to see if they were linked to chromosome 11. Although some tuberous sclerosis complex families showed weak linkage to chromosome 11, no independent groups were able to confirm linkage to chromosome 11. The difficulties in confirming or refuting linkage in tuberous sclerosis complex were compounded by the lack of large, multigenerational families available for study .16 In an effort to resolve the contradictory evidence, an international collabo-ration analyzed data from 111 families, and at a 1991 meeting devoted to tuberous sclerosis complex, which was sponsored by the New York Academy of Sciences, Haines et all' reported that a locus on chromosome 9 accounted for approximately one third of the families, and a locus on chromosome 11 was possible. At the same meeting, a single large family from New Zealand was reported that excluded linkage to both chromosomes 9 and 11,1' suggesting linkage to perhaps a third locus. When Fahsold et alI8 reported linkage to chromsome 12q in December 1991, the New Zealand family had already been tested for that linkage and had also excluded it. Furthermore, no other groups were able to confirm a linkage of tuberous sclerosis complex to chromosome 12. Using markers from all three candidate regions for tuberous sclerosis complex on chromsomes 9, 11, and 12, one study found that 14 of 16 (87.5%) tuberous sclerosis complex families showed no evidence of linkage.l9 Thus, evidence from individual groups as well as the international collaboration suggested that the majority of tuberous sclerosis complex families were not linked to a known chromosomal locus.
After the analysis of the international collaborative data in 1991, several groups in the United States decided that one way to find the major unlinked locus would be to focus on the families that were not linked to chromosome 9. As a result of this decision to focus on tuberous sclerosis complex families that were not linked to chromosome 9, ie, unlinked families, a collaboration was formed among investigators working at four different institutions: Duke University Medical Center, Massachusetts General Hospital, University of Texas-Houston, and University of California-Irvine. Five families with 85 members, of whom 47 had tuberous sclerosis complex, were prospectively selected because they fulfilled two criteria: (1) each was large enough to independently provide a lod score greater than 2, and (2) the family was not linked to chromosome 9q. A genomic screen was instituted in which the families were tested with multiple highly informative DNA markers. Testing of the tuberous sclerosis complex families with 115 markers distributed over 21 of the 22 pairs of autosomal chromosomes failed to find linkage.
Failure of the genomic screen to detect the location of the tuberous sclerosis complex gene dictated a different approach. Another strategy that has been used to find linkage has been that of testing with a marker for a candidate gene, ie, a gene that has a function that potentially could make it the gene for the disease in question. In the case of tuberous sclerosis complex, the gene for polycystic kidney disease was a reasonable candidate for the tuberous sclerosis complex gene because both disorders involve polycystic kidneys. Markers for polycystic kidney disease type 1 had previously been tested for linkage to tuberous sclerosis complex by several investigators, but at that time, markers generally had only two or a few alleles and were insufficiently informative to either confirm or refute linkage. Because of the failure of the genomic screen to discover the major unlinked locus, a new marker 2° for polycystic kidney disease type 1 was used in early 1992 to test the five tuberous sclerosis complex families. Analysis of this highly informative marker, D16S283 (SM7), the closest marker on the proximal side of the polycystic kidney disease type 1 locus on chromosome 16p13, was based on the variable lengths of simple sequence repeats in the DNA at the D16S283 locus.
Testing the five families with D16S283 resulted in a cumulative lod score of 9.50 at a recombination fraction (0) of 0.02.6 Because the lod score is based on a logarithm, 9.50 represents an exponent yielding odds in favor of linkage greater than 10 billion to 1. The four groups forming the initial collaboration have now tested many families, including smaller ones that were not part of the initial collaboration, and have found that the majority of tuberous sclerosis complex families are linked to chromosome 16p13, with the minority remaining linked to chromosome 9.21-24 The data do not support linkage to any other specific loci. It now seems likely that tuberous sclerosis complex is due to dysfunction of a gene on either chromosome 9 or chromosome 16.
Relationship of Tuberous Sclerosis Complex to Polycystic Kidney Disease Type 1
Although it now seems certain that a major locus for tuberous sclerosis complex is near the locus for polycystic kidney disease type 1, it remains possible that the relationship is entirely fortuitous. Even though the polycystic kidneys of tuberous sclerosis complex and polycystic kidney disease type 1 are clinically and radiologically indistinguishable, the histology of the cysts differs between tuberous sclerosis complex and polycystic kidney disease type 1.25 A histologic difference does not exclude a genetic relationship, and the histologic difference could potentially reflect part of the differing manifestations if tuberous sclerosis complex and polycystic kidney disease type 1 are allelic variants, parts of a contiguous gene deletion syndrome, or if both genes reside in an area of dynamic DNA mutation composed of various lengths of triplet repeats.26 At this time, it is not known if the clinical manifestations (eg, kidney disease) differ between the two genetic forms of tuberous sclerosis complex.
Future Directions
An initial effort will be directed at determining the proportion of tuberous sclerosis complex families that are linked to either chromosome 9 or 16, thereby enabling an accurate estimate of genetic locus heterogeneity. However, the major effort will be directed at discovering markers that flank the tuberous sclerosis complex genes and using techniques such as long-range restriction mapping and chromosomal and complementary DNA walking to define the areas occupied by the tuberous sclerosis complex genes (ie, fine mapping). Once a small enough area is delimited, the DNA of tuberous sclerosis complex patients can be sequenced and cloned so that it can be compared with normal DNA to determine the presence of mutations such as deletions, point mutations, or variation in triplet repeats. Identification and sequencing of the tuberous sclerosis complex genes should then lead to prediction of the protein products, detection of the messenger RNA transcripts, determination of specificity of tissue expression of the genes, and delineation of the functions of the protein products. Eventually, these should culminate in an understanding of the molecular pathophysiology of tuberous sclerosis complex which would perhaps allow the design of specific treatments for tuberous sclerosis complex patients.
DNA Diagnosis
Prenatal diagnosis of tuberous sclerosis complex using linked DNA markers was attempted in 1987,10 before it was realized that more than one genetic locus was involved. Because it is now known that tuberous sclerosis complex is genetically heterogeneous, the only families that can be considered at this point for either prenatal diagnosis or diagnosis of asymptomatic (or mildly symptomatic) individuals using linkage techniques are those that are large enough to independently demonstrate linkage to one of the two loci on either chromosome 9 or 16. As mentioned above, most of the known tuberous sclerosis complex families are too small to confidently determine that they are linked to a specific locus, and therefore they are not candidates for prenatal diagnosis. In the near future, as consensus is reached as to whether all sufficiently large families are linked to either chromosome 9 or 16 (as opposed to yet a third locus), the likelihood that a family is linked to either the chromosome 9 or 16 locus could be calculated 16 with a greater degree of certainty. For families that could be confidently assigned to one of the two loci, blood samples could be obtained from multiple affected and unaffected family members as well as the fetus or individual in question, and a diagnosis could be offered. The accuracy of the diagnosis using linkage techniques would increase with increasing proximity of the DNA markers to the tuberous sclerosis complex genes and the availability of markers that flank the loci. If, in the future, the entirety of the tuberous sclerosis complex genes can be cloned, and the various mutations causing tuberous sclerosis complex are determined, then analysis of an individual's DNA for a causative mutation will allow a direct diagnosis of tuberous sclerosis complex. Although not offered currently, it is hoped that diagnosis of asymptomatic individuals and prenatal diagnosis of tuberous sclerosis complex by DNA linkage analysis will be available in the near future.
